The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Alkermes Inc  (ALKS) Trade Now »     Rate ALKS  -  Discuss ALKS  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
50.0%
Top:
100.0%
Rate ALKS:



ALKS Analysis & Videos »


ALKS: Bull or Bear?

FDA, Clinical Trial Calendar Updates: Acorda, Alkermes, GTx Graphic_rating_buy ALKS
Mikerun
73%
 +31.83%
in 78 days
Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars .
 
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete r...
By  Mike Havrilla   (+1.04%  risk: conservative)  04/23/09 Comment


A Calendar of Expected Clinical Trial Results Graphic_rating_buy ALKS
Mikerun
73%
 -24.07%
in 102 days
(closed on 04/23/09)

A Calendar of Expected Clinical Trial Results

<>

The accompanying table [click to enlarge] includes 58 entries of expected clinical trial results in addition to pending FDA applications for new product approvals + a list of companies which will be required to re-submit their applications due to complete response letters from the agency.

See my recent article on 20 emerging healthcare stocks to watch in 2009 for more details on some of the companies included in the accompanying calendar, in addition to the following companies with near-term catalysts in...
By  Mike Havrilla   (+1.04%  risk: conservative)  01/11/09 Comment


Updated FDA Calendar Graphic_rating_buy ALKS
Mikerun
73%
 +5.25%
in 29 days
(closed on 01/11/09)

Updated FDA Calendar: Buying Cypress Bioscience

<>

The accompanying table [click to enlarge] includes a weekly update of 71 expected FDA decision dates as part of the ETF Innovators [ETFI] New Drug Regulatory Decision Catalyst Index. Since my article last week , the following action has taken place at FDA:

1.) Pain Therapeutics (PTIE) & King Pharma (KG) lost 21% and 7%, respectively, today after receiving a complete response letter from the FDA for their abuse-resistant form of controlled-release oxycodone, which is designed to deter the abuse and diver...
By  Mike Havrilla   (+1.04%  risk: conservative)  12/12/08 Comment


Get free stock alert for ALKS:
Your Email Address:


Alkermes (ALKS): Buyback boosts biotech Graphic_rating_buy ALKS
-33.31%
in 349 days

Filed under: Newsletters, Stocks to Buy

"Alkermes (NASDAQ: ALKS) recently produced a two-pronged positive surprise; an increase in the size of their already existing stock buyback program and a boost in their financial guidance," says John McCamant.

In his Medical Technology Stock Letter, the biotech sector expert looks at this firm which focuses on treatments for central nervous system disorders, alcohol depenence, and schizophrenia. Here is his review.

<>"Both of these moves were made possible by the announcement that ALKS has received a $40 million payment from Eli Lilly, their former partn...
By  Steven Halpern   (-8.76%  risk: moderate)  07/25/08 Comment


Alkermes (ALKS): Buyback boosts biotech bet Graphic_rating_buy ALKS
16%
 -17.23%
in 374 days

"Alkermes (NASDAQ: ALKS) recently produced a two-pronged positive surprise; an increase in the size of their already existing stock buyback program and a boost in their financial guidance," says John McCamant.

In his Medical Technology Stock Letter, the biotech sector expert looks at this firm which focuses on treatments for central nervous system disorders, alcohol depenence, and schizophrenia. Here is his review.

<>"Both of these moves were made possible by the announcement that ALKS has received a $40 million payment from Eli Lilly, their former partner for the now defunct AIR Insulin progra...
By  The Stock Advisors   (-31.04%  risk: moderate)  06/30/08 Comment


Pipeline Issues Keep ALKS a Hold ALKS
-18.42%
in 386 days
We believe it is subject to heightened risks of additional pipeline failures that may hamper the companyÂ?s progress towards its stated goals.
By  Zacks.com   (-20.83%  risk: moderate)  06/18/08 Comment


Alkermes (ALKS): Price cycles in bullish 'pennant' consolidation pattern Graphic_rating_buy ALKS
-18.81%
in 386 days

Filed under: Good news, Johnson and Johnson (JNJ), Bristol-Myers Squibb (BMY), Technical Analysis, Stocks to Buy

<>Alkermes (NASDAQ: ALKS) is a biotechnology company that makes extended-release products for the treatment of chronic diseases. The firm developed and manufactures Vivitrol, a treatment for alcohol dependence that partner Cephalon (NASDAQ: CEPH) markets in the United States. It also makes Risperdal Consta, a long-acting version of Janssen's schizophrenia medication Risperdal. Alkermes' pipeline includes extended-release injectable, pulmonary and oral products for the treatment of c...
By  Larry Schutts   (-31.52%  risk: moderate)  06/18/08 Comment





People Bullish on ALKS

Mikerun
Mike Havrilla
Principal
73%
2 mos ago

Steven Halpern
Tracked Blogger
56%
11 mos ago

The Stock Advisors
Analyst
16%
about 1 year ago

Larry Schutts
Tracked Blogger
29%
about 1 year ago

mbroudo
Associate
21%
about 1 year ago


People Bearish on ALKS

A T
Associate
61%
about 1 year ago

traderthoughts
Associate
 4 %
over 2 years ago

ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +42.42% 274
2 Gerald Greene 18.14 +54.81% 140
3 stockmarketfunding.com 17.66 +22.12% 35
4 akiralegrand 13.47 +15.91% 49
5 anup2104 12.13 +34.41% 13


POPULAR STOCKS
Symbol Company Name Sentiment
YHOO Yahoo! Inc
AMZN Amazoncom Inc
FSLR First Solar Inc.
BIDU Baiducom Inc ADS
ETFC E*Trade Financial Corp
AAPL Apple Computer Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on ALKS


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About Alkermes Inc - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch